Advertisement

Picture Kentro Design Corporate and Web Design Berlin 600x60px

Deals > All

Total search results: 10293 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 101 102 103  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Orchard Therapeutics–Sirion Biotech: gene therapy manufacturing technology, 201812– license for stem cell gene therapies 2018-12-14
Pharvaris–Kurma: investment, 201812 existing founding investor Kurma Biofund II 2018-12-14
Step Pharma–Kurma: investment, 201812 existing founding investor Kurma Biofund II 2018-12-14
Mestrelab Research–Bruker Corp: investment, 201812 acquisition of majority share €na by Bruker incl strateg collab + partnership 2018-12-13
Imprint Analytics–SGS: credit, 201812– convertible loan as part of strategic partnership 2018-12-12
Santhera–SEVERAL: investment, 201812 capital increase CHF23.5m with 3.134m shares at CHF7.5/share 2018-12-12
SGS–Imprint Analytics: food analysis, 201812– collab strategic partnership isotope analysis for proof of origin + authenticity food testing 2018-12-12
Synthace–SEVERAL: investment, 201812 financing round Series B $25.6m led by Horizons Ventures 2018-12-12
AstraZeneca–Cancer Research UK: functional genomics, 201812– collab establishment of joint venture Functional Genomics Centre in Cambridge 2018-12-10
Chiesi–Centogene: genetic services, 201812– collab epidemiology study in lysosomal storage diseases with focus on AM by Centogene for Chiesi GmbH 2018-12-10
Genomics plc–F-Prime: investment, 201812 financing round Series B 2nd closing totalling £8m from Foresite Capital + F-Prime Capital 2018-12-10
Genomics plc–Foresite Capital: investment, 201812 financing round Series B 2nd closing totalling £8m from Foresite Capital + F-Prime Capital 2018-12-10
Genomics plc–SEVERAL: investment, 201812 financing round Series B 2nd closing £8m from Foresite Capital + F-Prime Capital bringing total round to £33m 2018-12-10
genOway–Merck (DE): CRISPR technology, 201812– collab strategic alliance €na incl ww excl license to produce + sell genome-edited rodent models 2018-12-10
Lonza–General Electric: biologics manufacuturing technology, 201812–2020 supply biologics facility in Guangzhou using KUBio platform by GE Healthcare 2018-12-10
Spatial Transcriptomics–10x Genomics: investment, 201812 acquisition of Spatial by 10x Genomics 2018-12-10
Alacris–Seedmatch: financial services, 201812– crowdfunding campaign up to €800k via Seedmatch platform 2018-12-06
Alacris–SEVERAL: investment, 201812– crowdfunding campaign up to €800k via Seedmatch platform 2018-12-06
Hookipa–Valneva: drug development services, 201812–202111 collab + manufacturing agreem for developm of immunotherapies with Valneva Sweden AB 2018-12-06
Merck (DE)–Cyclica: drug discovery services, 201812– collab using cloud-based proteome screening platform for small molecule drug development 2018-12-06
Novartis–Qiagen: molecular companion diagnostics, 201812– collab devlepm of CDx for alpelisib (BYL719) 2018-12-06
AC Immune–Hopp Group: investment, 201812 existent investment dievini Hopp owns 27% of AC Immune SA 2018-12-05
Apogenix–Hopp Group: investment, 201812 existent investment dievini Hopp owns 92% of Apogenix AG 2018-12-05
Cassiopea–Hopp Group: investment, 201812 existent investment dievini Hopp owns 1% of Cassiopea SpA 2018-12-05
Cosmo Pharmaceuticals–Hopp Group: investment, 201812 existent investment dievini Hopp owns 5% of Cosmo SpA 2018-12-05
CureVac–Hopp Group: investment, 201812 existent investment dievini Hopp owns 80% of CureVac AG 2018-12-05
Heidelberg Pharma–Hopp Group: investment, 201812 existent investment dievini Hopp owns 83% of Heidelberg Pharma AG 2018-12-05
Immatics–Hopp Group: investment, 201812 existent investment dievini Hopp owns 38% of Immatics GmbH 2018-12-05
Joimax–Hopp Group: investment, 201812 existent investment dievini Hopp owns 85% of Joimax GmbH 2018-12-05
Molecular Health–Hopp Group: investment, 201812 existent investment dievini Hopp owns 95% of Molecular Health GmbH 2018-12-05
Novaliq–Hopp Group: investment, 201812 existent investment dievini Hopp owns 93% of Novaliq GmbH 2018-12-05
Oryzon Genomics–Citigroup: investor conference, 201812 supply service Oryzon attends Citi Global Healthcare Conference NY 2018-12-05
Sillages Paris–L’Oréal: investment, 201812 acquisition of minority share by BOLD fund as inaugural investment of BOLD 2018-12-05
Anagenesis–Alsace (govt): investment, 201812 financing round Series A 1st closing totalling €3m incl existing investor Cap Innov’Est 2018-12-04
Anagenesis–Boehringer: investment, 201812 financing round Series A 1st closing totalling €3m incl new investor BIVF 2018-12-04
Anagenesis–SEVERAL: investment, 201812 financing round Series A €3m 1st closing from BIVF + Cap Innov’Est 2018-12-04
Boehringer–Domain Therapeutics: drug discovery services, 201812– collab + license agreem €na discovery of GPCR-targeting CNS drugs 2018-12-04
Leo Pharma–Evotec: drug discovery services, 201812– collab €na integrated drug discovery to generate leads against innovative dermatic targets 2018-12-04
Argen-X–JnJ: investment, 201812 investment $200m of 1.767m new shares at €100.02/share representing 4.68% shareholding by JJDC 2018-12-03
JnJ–Argen-X: cusatuzumab, 201812– collab + license agreem ww with Cilag GmbH for up to $1.6b incl $300m upfront cash 2018-12-03
Tesaro–GSK: investment, 201812– acquisition $5.1b (£4b) in cash incl net debt assumption of Tesaro Inc by GSK ANNOUNCED 2018-12-03
Aprea–SEVERAL: investment, 201812 financing round Series C €50m led by new investor Redmile Group 2018-12-02
Igem Therapeutics–SEVERAL: investment, 201811 financing round Series £3m final closing bringing total round to £5m 2018-11-30
CRISPR Therapeutics–Barclays: investor conference, 201811 supply service CRISPR Tx presents at Barclays Gene Editing & Gene Therapy Summit 2018-11-29
Argen-X–Piper Jaffray: investor conference, 201811 supply service Argenx presents at Piper Jaffray Healthcare Conference in NYC 2018-11-28
CRISPR Therapeutics–Piper Jaffray: investor conference, 201811 supply service CRISPR Therapeutics at Piper Jaffray Healthcare Conference 2018 2018-11-28
F2G Ltd–Evercore: investor conference, 201811 supply service F2G presents at Evercore ISI HealthCONx Conference 2018 2018-11-28
Hookipa–DarwinHealth: personalised medicine, 201811– collab research + license agreem to develop I-O treatments using systems biology 2018-11-28
ABP (NL)–Optimum Strategic Communications: public relations, 201811 service existent by Optimum for Inkef Capital 2018-11-27
Allogene Therapeutics–Piper Jaffray: investor conference, 201811 supply service Allogene presents at Piper Jaffray Healthcare Conference in NYC 2018-11-27
Argen-X–Evercore: investor conference, 201811 supply service Argenx presents at Evercore ISI HealthCONx Conference 2018 2018-11-27
Celyad–Piper Jaffray: investor conference, 201811 supply service Celyad participates at Piper Jaffray Healthcare Conference in NYC 2018-11-27
Engitix–Instinctif Partners: public relations, 201811 service existent by Instinctif 2018-11-27
Engitix–SEVERAL: investment, 201811 financing round Series A £5m led by private investor 2018-11-27
Genomics Medicine Ireland–Wuxi PharmaTech: investment, 201811 acquisition of Ireland Medicine Ireland by WuXi NextCode 2018-11-27
Jecure Therapeutics–Roche: investment, 201811 acquisition of Jecure by Genentech from Versant Ventures 2018-11-27
Nabriva–Piper Jaffray: investor conference, 201811 supply service Nabriva presents at Piper Jaffray Healthcare Conference in NYC 2018-11-27
SpinDiag–SEVERAL: investment, 201811 financing round Series A €3m 2018-11-27
X4 Pharmaceuticals–Arsanis: investment, 201811– reverse merger with former X4 owners to hold 70% + Arsanis to be renamed X4 ANNOUNCED 2018-11-27
Adrenomed–HBM: investment, 201811 financing round Series D totalling €24m incl new + co-lead investor HBM Healthcare Investments 2018-11-26
Adrenomed–MC Services: public relations, 201811 service existent by MC Services 2018-11-26
Adrenomed–SEVERAL: investment, 201811 financing round Series D €24m with new + co-lead investors Wellington + HBM plus existing investors 2018-11-26
Adrenomed–Wellington Partners: investment, 201811 financing round Series D totalling €24m incl new + co-lead investor Wellington Partners 2018-11-26
Bayer–Cyclica: drug discovery services, 201811– collab using cloud-based proteome screening platform for small molecule drug development 2018-11-26
Fluidic Analytics–Amadeus Capital: investment, 201811 financing round totalling $31m incl existing + co-investor Amadeus Capital Partners 2018-11-26
Fluidic Analytics–BGF: investment, 201811 financing round totalling $31m incl new + co-investor BGF 2018-11-26
Fluidic Analytics–Delin Ventures: investment, 201811 financing round totalling $31m incl new + co-investor Delin Ventures 2018-11-26
Fluidic Analytics–Draper Esprit: investment, 201811 financing round totalling $31m incl existing + lead investor Draper Esprit 2018-11-26
Fluidic Analytics–IQ Capital: investment, 201811 financing round totalling $31m incl existing + co-investor IQ Capital 2018-11-26
Fluidic Analytics–SEVERAL: investment, 201811 financing round $31m led by existing investor Draper Esprit 2018-11-26
Immune Regulation–Instinctif Partners: public relations, 201811 service existent by Instinctif 2018-11-26
Suntory–BRAIN: food ingredients, 201811– collab €na developm natural beverage solutions with SBFE 2018-11-26
Oxford BioMedica–United Kingdom (govt): grant, 201811 Innovate UK grant £2m to support digitallisation of gene/cell therapy production 2018-11-23
Celyad–Bryan Garnier: investor conference, 201811 supply service Celyad participates at Bryan Garnier Annual Healthcare Conference in Paris 2018-11-22
Erytech–Infopro Digital: investor conference, 201811 supply service Erytech at Actionaria 2018 in Paris 2018-11-22
F2G Ltd–EU (govt): credit, 201811– InnovFin €24m loan from EIB to F2G Biotech GmbH for antifungals r+d 2018-11-22
Kyowa Hakko Kirin–GSK: daprodustat, 201811– collab €na commercialisation of daprodustat in Japan by Kyowa Hakko Kirin 2018-11-22
Evotec–Immuneering: drug discovery software, 201811– collab AI-driven small-molecule drug discovery for hereditary metabolic diseases 2018-11-21
OMass–SEVERAL: investment, 201811 financing round Series A £14m led by new investor Syncona Ltd plus Oxford Sciences Innovation 2018-11-21
OMass–Univ Oxford: investment, 201811 financing round Series A totalling £14m incl existing + co-investor Oxford Sciences Innovation 2018-11-21
OMass–Wellcome Trust: investment, 201811 financing round Series A totalling £14m incl new + lead investor Syncona Ltd 2018-11-21
BridgeBio–Leo Pharma: investment, 201811 acquisition minority stake in PellePharm Inc plus r+d funding + plus option to aquire PellePharm 2018-11-20
Quarton International–Cowen: investment, 201811–201901 acquisition of Quarton by Cowen 2018-11-20
Stilla Technologies–Alize RP: public relations, 201811 service existent PR EU by Alize RP 2018-11-20
Stilla Technologies–BNP Paribas: investment, 201811 financing round Series A totalling €16m incl co-investor BNP Paribas Développement 2018-11-20
Stilla Technologies–Idinvest Partners: investment, 201811 financing round Series A totalling €16m incl co-investor Idinvest Partners 2018-11-20
Stilla Technologies–Illumina: investment, 201811 financing round Series A totalling €16m incl lead investor Illumina Ventures 2018-11-20
Stilla Technologies–Kurma: investment, 201811 financing round Series A totalling €16m incl co-investor Kurma Partners 2018-11-20
Stilla Technologies–LBO France: investment, 201811 financing round Series A totalling €16m incl co-investor LBO France 2018-11-20
Stilla Technologies–Paris Saclay Seeds: investment, 201811 financing round Series A totalling €16m incl co-investor Paris Saclay Seeds 2018-11-20
Stilla Technologies–SEVERAL: investment, 201811 financing round Series A €16m led by Illumina Ventures 2018-11-20
Inflazome–Forbion: investment, 201811 financing round Series B totalling €40m incl new + lead investor Forbion Capital Partners 2018-11-19
Inflazome–Fountain Healthcare Partners: investment, 201811 financing round Series B totalling €40m incl existing + co-investor FHP 2018-11-19
Inflazome–Longitude Capital: investment, 201811 financing round Series B totalling €40m incl new + co-investor Longitude Capital 2018-11-19
Inflazome–Novartis: investment, 201811 financing round Series B totalling €40m incl existing + co-investor Novartis Venture Fund 2018-11-19
Inflazome–SEVERAL: investment, 201811 financing round Series B €40m from Forbion + Longitude Capital + NVF + Fountain Healthcare Partners 2018-11-19
Lonza–Chaim Sheba Medical Center: cell therapy manufacturing technology, 201811 collab existent to evaluate + test Cocoon technology 2018-11-19
Roche–Immunocore: ImmTAC technology, 201811– collab expansion co-developm of IMC-C103C with $100m upfront/near-term with Genentech 2018-11-19
Noxxon–SEVERAL: investment, 201811 capital increase €6.21m incl €4.4m from Acuitas Capital LLC 2018-11-16
Aimmune Therapeutics–Leucadia: investor conference, 201811 supply service Aimmune attends Jefferies 2018 London Healthcare Conference 2018-11-15
next pagenext page 1 2 3 ... 101 102 103  next pagenext page



Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 600x60px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

» top